In Vitro combined effects of cefozopran/teicoplanin and cefozopran/vancomycin on methicillin-resistant Staphylococcus aureus

Journal of Chemotherapy

Volumn 15, Issue 1, 2003, Pages 31-36

  Toyokawa, Masahiro ^a   Asari, S ^b   Nishi, I ^a   Horikawa, M ^a   Tsukamoto, H ^a   Sunada, A ^a   Ueda, A ^a   Iwatani, Y ^b  

^a OSAKA UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Cefozopran; In vitro effects; MRSA; Multidrug therapy; Teicoplanin; Vancomycin

Indexed keywords

CEFOZOPRAN; METICILLIN; TEICOPLANIN; VANCOMYCIN;

ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; DRUG EFFECT; DRUG POTENCY; GRAM NEGATIVE BACTERIUM; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; STAPHYLOCOCCUS INFECTION; TIME;

EID: 0242500913     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.1.31     Document Type: Article

References (12)

1. Niizuma K. Clinical characteristics of MRSA infections, with particular emphasis on polymicrobial infections. Kansen to Kokinyaku [Infections and Antimicrobials] 2001; 4 Suppl 1: 16-20.
2. Tsujino M. Combined effects of antibiotics in the treatment of MRSA infections: specifics of use. Kansen to Kokinyaku [Infections and Antimicrobials] 2001; 4 Suppl 1: 27-32.
3. Kaatz GW, Seo M, Dorman MJ, et al. Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis. J Infect Dis 1990; 162: 103-108.
4. Hanaki H. Normal or existent anti-MRSA drugs, and preventive steps of acquisitive resistance. Kagaku Ryoho no Ryoiki [Antibiotics and Chemotherapy] 2001; 17: 233-240.
5. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-136.
6. Toyokawa M, Asari S, Horikawa M, et al. Problems in the checkerboard method using senal twofold dilutions. Nihon Kagaku Ryoho Gakkai Zasshi [Chemotherapy] 1994; 42: 841-848.
7. Watanabe A. Current status of antibiotic treatment of MRSA infections and use of anti-MRSA drugs (2) Respiratory infections. Kansen to Kokinyaku [Infections and Antimicrobials] 2001; 4 Suppl 1: 38-43.
8. Toyokawa M, Asari S, Horikawa M, et al. In vitro combined effects of cefotiam/vancomycin, cefotiam/arbekacin, and minocycline/vancomycin on MRSA. Nihon Kagaku Ryoho Gakkai Zasshi [Chemotherapy] 1996; 44: 590-594.
9. Hanaki H, Hiramatsu K. Combination effect of teicoplanin and various antibiotics against hetero-VRSA and VRSA. Kansenshogaku Zasshi [The Journal of the Japanese Assoc. for Infectious Diseasesl 1999; 73: 1048-1053.
10. Otsuka Y, Yoshibe T, Namioka M, et al. Combination effects of teicoplanin and β-lactams on MRSA. Jpn J Antibiot 2000; 53: 643-651.
11. Tsuji A. Cefozopran II: antibacterial action. Data gathered from the 40th Regional New Drug Symposium of the Japan Society of Chemotherapy, Okayama, Japan. December 1992:19-56.
12. Takahashi T, Matsumoto F, Miyazaki S. Comparison of in vitro antibacterial activity of arbekacin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus. Nihon Kagaku Ryoho Gakkai Zasshi [Chemotherapy] 1999; 47: 103-107.